“…Based on a retrospective cohort study, LOC339059 expression was determined to be down-regulated in primary gastric cancer tissues compared with adjacent tissues, and its low expression predicts a poor survival time after surgery. Furthermore, its level of expression was found to be correlated with the expression of some immune response genes. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…A combination of experimental approaches, including Western blotting, quantitative real-time reverse transcription‑polymerase chain reaction (qRT-PCR), and enzyme-linked immunosorbent assay (ELISA), confocal microscopy and rescue studies, were used to explore the underlying mechanisms of GPR65’s action in liver fibrosis. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…According to the quite rapidly developed vaccines in a fast window time, large investigations to assess the probable vaccine-related adverse events are crucially required. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…All six samples were analyzed as a lineage of the dominant omicron sub-lineage variant BA.2.3 at the time of the patients' first COVID-19 diagnosis. [Figure: see text] [Figure: see text] CONCLUSION: Persistent SARS-CoV-2 infection in patients receiving B-cell depleting treatment showed sustained viral shedding and low neutralizing antibody response can cause intrahost viral evolution. …”
Enlace del recurso
Enlace del recurso

“…Susceptibility rates for both β-lactam/β-lactamase inhibitors was higher than FDC, suggesting they may be preferred for tx in the absence of timely susceptibility testing. The activity of each agent is compromised by NDM-producing strains that harbor PBP3 mutations. …”
Enlace del recurso
Enlace del recurso

“…Disease IRs were generally higher in Medicaid children, particularly at the start of the study period, but also declined more significantly over time compared to IRs in CCAE children. DISCLOSURES: Salini Mohanty, DrPH, MPH, Employee of Merck & Co., Inc.: Stocks/Bonds Nicolae Done, PhD, Merck & Co., Inc.: Grant/Research Support Qing liu, PhD, Merck & Co., Inc.: Advisor/Consultant Yan Song, PhD, Merck & Co., Inc.: Grant/Research Support Katherine Gaburo, n/a, Merck & Co., Inc.: I am an employee of Analysis Group, Inc., which received consulting fees for participation in this research Travis Wang, MS, MBBS, Merck & Co., Inc.: Grant/Research Support Meghan White, PharmD, Merck: Employee|Merck: Stocks/Bonds Jessica P. …”
Enlace del recurso
Enlace del recurso

“…SARS-CoV-2 RNA collected in Buffer AVL was extracted using QIAamp Viral RNA mini kit and quantified by the real-time quantitative PCR (RT-qPCR) targeting the N2 region. …”
Enlace del recurso
Enlace del recurso

“…METHODS: Data from the Investigating Respiratory Viruses in the Acutely Ill (IVY) Network were used to conduct a case-control analysis measuring bivalent vaccine effectiveness (VE) against COVID-19–associated hospitalization over time. During September 8, 2022–April 1, 2023, immunocompetent, hospitalized adults aged ≥65 years with COVID-19-like illness were enrolled at 25 hospitals in 20 U.S. states. …”
Enlace del recurso
Enlace del recurso

“…Zamparo, MPH, Pfizer Inc.: Full Time Employee|Pfizer Inc.: Stocks/Bonds Deborah S. …”
Enlace del recurso
Enlace del recurso

“…Cases were those who experienced a graft rejection during the study period and eligible controls were those who had not experienced a rejection at the time of a given case. Controls were randomly selected via risk-set sampling and matched in a 3:1 ratio to cases on age, sex, and transplant date (±12 weeks). …”
Enlace del recurso
Enlace del recurso

“…METHODS: A population-based, multi-cohort, decision-analytic Markov model was developed to estimate the public health impact and cost-effectiveness of a PCV20 catch-up program from both a societal (base-case) and health-care perspective over a 10-year time horizon. In the model a single supplemental dose was assumed to be given to 63% of children aged 14-59 months who had received a complete schedule of PCV13. …”
Enlace del recurso
Enlace del recurso

“…DISCLOSURES: Lee Harrison, MD, GSK: Advisor/Consultant|Merck: Advisor/Consultant|Pfizer: Advisor/Consultant|Sanofi: Advisor/Consultant Tamara Pilishvili, PhD MPH, GSK: Employed by GSK since February 2023. At the time of data collection and analysis for this work was employed by the CDC…”
Enlace del recurso
Enlace del recurso

“…Among the myocarditis cases, elevated BMI was common (7/11, 63.6% overweight/obese), and comorbidities were otherwise rare. At the time of initial infection, 10/11 (90.9%) were unvaccinated. …”
Enlace del recurso
Enlace del recurso

“…Clinical symptoms and severity did not significantly differ between groups, nor did the time from last vaccination to infection (IDP: 140 days, HV: 161 days, p=0.28). …”
Enlace del recurso
Enlace del recurso

“…DISCLOSURES: Samantha Nicolau, PhD, Sanofi Pasteur: full time research scientist Patricia J. Simner, PhD, Affinity Biosensors: Grant/Research Support|BD Diagnostics: Advisor/Consultant|BD Diagnostics: Grant/Research Support|Entasis: Advisor/Consultant|GeneCapture: Stocks/Bonds|Merck: Advisor/Consultant|OpGen Inc: Board Member|OpGen Inc: Grant/Research Support|OpGen Inc: Honoraria|Qiagen Sciences Inc: Advisor/Consultant|Qiagen Sciences Inc: Grant/Research Support|Shionogi Inc: Advisor/Consultant|T2 Biosystems: Grant/Research Support David P. …”
Enlace del recurso
Enlace del recurso

“…Kaplan-Meier curves between patients in the FMT cohort and those in the control group (n=82) revealed the same rate of decolonization over time (p=0.9). Microbiota composition analyses post-FMT revealed significantly higher bacterial species richness and alpha diversity in responders versus non-responders (Fig1A,B), and specific taxa including Faecalibacterium prausnitzii, Parabacteroides distasonis, Collinsella aerofaciens, Alistipes finegoldii and Blautia_A sp900066335 were associated with response (Fig.2). …”
Enlace del recurso
Enlace del recurso

“…DISCLOSURES: Natalia Zemlianskaia, PhD, Janssen Pharmaceuticals: Employee|Janssen Pharmaceuticals: Stocks/Bonds Amanda Zheutlin, PhD, Janssen Pharmaceuticals: Employee Yoshihiko Murata, MD, PhD, Gilead Sciences: Current employee of Gilead Sciences|Gilead Sciences: Stocks/Bonds|Merck Research Laboratories: Listed as co inventor in a patent|Merck Research Laboratories: Former employee of Merck Research Laboratories|ViiV Healthcare: Former employee of ViiV Healthcare Jyotsna Bhattacharya, MD, FAAP, Janssen Pharmaceuticals: Current Employee|Janssen Pharmaceuticals: Stocks/Bonds Geoffroy Coteur, PhD, Janssen Pharmaceutica: Honoraria|Janssen Pharmaceutica: Stocks/Bonds Gabriela Ispas, PhD, Janssen Pharmaceuticals: Current Employee|Janssen Pharmaceuticals: Stocks/Bonds Jorge Villacian, MD, Janssen Pharmaceuticals: Current Employee|Janssen Pharmaceuticals: Stocks/Bonds Jason Chien, MD, MS, Janssen Biopharma: Stocks/Bonds David Hong, MD, Janssen: Former employee|Janssen: Stocks/Bonds|Spero Therapeutics: Employee Jennings Xu, BA, Janssen Pharmaceuticals: Employee|Janssen Pharmaceuticals: Stocks/Bonds Breno Neri, PhD, Janssen R&D: Full time employment|Janssen R&D: Stocks/Bonds Khaled Sarsour, PhD, Janssen Pharmaceuticals: Employee|Janssen Pharmaceuticals: Stocks/Bonds Tripthi Kamath, PhD, Janssen Pharmaceuticals: Employee|Janssen Pharmaceuticals: Stocks/Bonds Xinggang lIU, MD, PhD, Janssen Pharmaceuticals: Current employee|Janssen Pharmaceuticals: Stocks/Bonds…”
Enlace del recurso
Enlace del recurso

“…VAN, DAP, and LZD also exhibited stable activity against these pathogens over time. S. dysgalactiae showed the largest changes in %S between periods but isolate numbers were low. …”
Enlace del recurso
Enlace del recurso

“…The majority of those enrolled did not require hospitalization, with only 2 of 154 (1.3%) hospitalized, both with MIS-C. 19% of participants were fully vaccinated at the time of their infection. Among 129 participants with an echo or an ECG, 4 (3.1% (95% CI 0.09%-7.7%)) had abnormalities attributed to COVID 19 (Table 2), including 1 MIS-C case. …”
Enlace del recurso
Enlace del recurso

“…Meropenem Target Concentrations [Figure: see text] Targeted concentrations to simulate percent time of unbound meropenem in serum and ELF above the MIC RESULTS: Serum targeted models reached the limit of detection by 24 hours with bactericidal activity through 96 hours (p< 0.05). …”
Enlace del recurso
Enlace del recurso